Niacin therapy unhelpful, occasionally harmful, study says

A combination drug containing niacin failed to lower the risk of heart attacks or strokes and even proved harmful for some with vascular disease, a study released Saturday reported.

Niacin, also known as , has for years been widely prescribed to lower "bad" LDL cholesterol and raise levels of "good" .

The link between high levels of and heart disease is well-documented, and doctors work to mitigate that risk with diet and as well as a variety of medications.

But even with these protocols in place, heart disease and stroke claim lives and cause damage, so scientists continue searching for ways to improve the treatment.

Niacin—in doses about 100 times higher than the recommended amount from food—was thought to be helpful.

Indeed, the used in the study—made by US Merck and combining extended release niacin with laropiprant—is already approved in 70 countries, though not the US.

But when tested against a placebo in more than 25,000 patients, it failed to reduce the numbers of heart attacks, strokes or other serious .

Even more worryingly, the study showed unexpectedly higher levels of bleeding and infections in the group taking the drug versus the placebo.

And the group taking the study drug also showed higher levels of other side effects, including new cases of diabetes and complications for previously-diagnosed diabetes, as well as rashes and diarrhea.

"We are disappointed that these results did not show benefits for our patients", said Jane Armitage, lead author of the study, which included more than 25,000 subjects.

But she and her fellow authors said the result is important, because it gives evidence that the risks of niacin outweigh the benefits when used with current treatments.

Armitage said it was unlikely the poor outcome could be linked to the second component of the drug, laropiprant, which was included to reduce the facial flushing caused by niacin.

The lack of benefit on heart attacks and strokes is consistent with another recent, smaller-scale study of niacin, which did not use laropiprant, and many of the side effects are known to be due to niacin, she explained.

Because of the results of this research, Merck has withdrawn its application for FDA approval of the drug and suspended its sale around the world.

add to favorites email to friend print save as pdf

Related Stories

Merck says cholesterol drug failed to show benefit

Dec 20, 2012

Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.

Recommended for you

Barriers preventing post-stroke care

Jul 24, 2014

For stroke victims, rehabilitation is crucial to their recovery. But a Flinders University study conducted in Singapore found that rehabilitation rates following discharge from hospital are poor because of gaps in the continuum ...

Home-based rehabilitation for CVD patients

Jul 24, 2014

Patients who are found to suffer from cardiovascular diseases often have long years of treatment ahead of them and are urged to drastically change their lifestyle. But what is probably the most difficult ...

New remote patient monitoring devices available

Jul 24, 2014

(HealthDay)—Several new remote patient monitoring devices with useful applications are available or under development, according to an article published July 8 in Medical Economics.

User comments